MX338629B - Composiciones farmaceuticas de ibuprofeno y un antagonista del receptor de h2. - Google Patents

Composiciones farmaceuticas de ibuprofeno y un antagonista del receptor de h2.

Info

Publication number
MX338629B
MX338629B MX2012013970A MX2012013970A MX338629B MX 338629 B MX338629 B MX 338629B MX 2012013970 A MX2012013970 A MX 2012013970A MX 2012013970 A MX2012013970 A MX 2012013970A MX 338629 B MX338629 B MX 338629B
Authority
MX
Mexico
Prior art keywords
ibuprofen
pharmaceutical compositions
receptor antagonist
compositions
effective amount
Prior art date
Application number
MX2012013970A
Other languages
English (en)
Other versions
MX2012013970A (es
Inventor
George Tidmarsh
Puneet Sharma
Iain Duncan
Original Assignee
Grünenthal S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grünenthal S A filed Critical Grünenthal S A
Publication of MX2012013970A publication Critical patent/MX2012013970A/es
Publication of MX338629B publication Critical patent/MX338629B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)

Abstract

En la presente, se proporcionan composiciones farmacéuticas de un antagonista de receptor de H2 e ibuprofeno. Las composiciones comprenden, por ejemplo, un núcleo y una cubierta separados por una capa de barrera, composiciones de bicapa o tricapa o formulaciones líquidas. También se proporcionan métodos para producir las composiciones farmacéuticas y métodos de tratamiento que comprenden administrar las composiciones farmacéuticas. También se proporciona un método para la administración de ibuprofeno en un sujeto en necesidad del tratamiento con ibuprofeno, en el cual se administra tres por día una composición farmacéutica que comprende una cantidad terapéuticamente efectiva de ibuprofeno y una cantidad terapéuticamente efectiva de un H2RA, tal como famotidina.
MX2012013970A 2010-06-01 2011-05-31 Composiciones farmaceuticas de ibuprofeno y un antagonista del receptor de h2. MX338629B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35035110P 2010-06-01 2010-06-01
US35159410P 2010-06-04 2010-06-04
PCT/US2011/038622 WO2011153168A1 (en) 2010-06-01 2011-05-31 Pharmaceutical compositions of ibuprofen and an h2 receptor antagonist

Publications (2)

Publication Number Publication Date
MX2012013970A MX2012013970A (es) 2013-03-21
MX338629B true MX338629B (es) 2016-04-26

Family

ID=45067050

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012013970A MX338629B (es) 2010-06-01 2011-05-31 Composiciones farmaceuticas de ibuprofeno y un antagonista del receptor de h2.

Country Status (5)

Country Link
US (2) US20130078287A1 (es)
BR (1) BR112012030708A2 (es)
CO (1) CO6640251A2 (es)
MX (1) MX338629B (es)
WO (1) WO2011153168A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2612238T3 (es) 2014-02-27 2017-05-12 Galenicum Health S.L. Composiciones farmacéuticas estables

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1264517B1 (it) * 1993-05-31 1996-09-24 Ekita Investments Nv Compressa farmaceutica atta al rilascio in tempi successivi dei principi attivi in essa veicolati
US20030035839A1 (en) * 2001-05-15 2003-02-20 Peirce Management, Llc Pharmaceutical composition for both intraoral and oral administration
US20040081695A1 (en) * 2002-09-28 2004-04-29 Sowden Harry S Dosage forms having an inner core and an outer shell
WO2004064815A1 (en) * 2003-01-21 2004-08-05 Smartrix Technologies Inc. Oral dosage formulation
FR2855756B1 (fr) * 2003-06-06 2005-08-26 Ethypharm Sa Comprime orodispersible multicouche
US8067451B2 (en) * 2006-07-18 2011-11-29 Horizon Pharma Usa, Inc. Methods and medicaments for administration of ibuprofen
US20070049641A1 (en) * 2005-08-24 2007-03-01 Rabindra Tirouvanziam Methods for treating and monitoring inflammation and redox imbalance cystic fibrosis
US8067033B2 (en) * 2007-11-30 2011-11-29 Horizon Pharma Usa, Inc. Stable compositions of famotidine and ibuprofen
JP5564490B2 (ja) * 2008-04-18 2014-07-30 リアタ ファーマシューティカルズ インコーポレイテッド 抗炎症性ファルマコアを含む化合物および使用法
US20100112054A1 (en) * 2008-10-23 2010-05-06 Appian Labs, Llc Tablets and discs with compartments with two or more drugs for release at certain intervals and with specific rates

Also Published As

Publication number Publication date
MX2012013970A (es) 2013-03-21
WO2011153168A1 (en) 2011-12-08
CO6640251A2 (es) 2013-03-22
BR112012030708A2 (pt) 2016-11-01
US20140322313A1 (en) 2014-10-30
US20130078287A1 (en) 2013-03-28

Similar Documents

Publication Publication Date Title
WO2013101897A3 (en) Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid
WO2013158680A3 (en) Compositions and methods comprising celecoxib or related compounds and dextromethorphan
HK1182619A1 (zh) 用於局部給藥的螺-羥吲哚化合物的藥物組合物及其作為治療劑的用途
MX2019000586A (es) Virus adenoasociados (aav) sflt-1 para usarse en el tratamiento de degeneración macular relacionada con la edad (amd).
WO2008131056A3 (en) Sustained release monoeximic formulations of opioid and nonopioid analgesics
WO2012098562A3 (en) Liquid oral compositions of lanthanum salts
WO2008131057A3 (en) Sustained release formulations of opioid and nonopioid analgesics
MY160728A (en) Morpholinothiazoles as alpha 7 positive allosteric modulators
MY156332A (en) Quinuclidine carbonate derivatives and medicinal composition thereof
WO2013090278A3 (en) Intranasal dexmedetomidine compositions and methods of use thereof
WO2012007159A3 (en) Novel gastro-retentive dosage forms
NZ606768A (en) Pharmaceutical compositions and methods of treatment
WO2011157416A3 (de) Transdermale verabreichung von memantin
EA201290734A1 (ru) Рифаксимин в форме порошка, способ его получения и композиции контролируемого высвобождения, содержащие указанный рифаксимин, полезные для достижения длительного эффекта
WO2011118976A3 (en) Pharmaceutical composition for the prevention or the treatment of non-alcoholic fatty liver disease and the method for prevention or treatment of non-alcoholic fatty liver disease using the same
TN2015000135A1 (en) Modified release formulations for oprozomib
MX2013000694A (es) Vitamina c y vitamina k libre de cromo, y composiciones de estas para tratar un estado o enfermedad en las que interviene nfkb.
WO2012113850A3 (en) (PYRIDIN-4-YL)BENZYLAMIDES AS ALLOSTERIC MODULATORS OF ALPHA 7 nAChR
WO2011064558A3 (en) Pharmaceutical composition
WO2010044097A3 (en) Novel dosage form of paliperidone and process for preparing the same
WO2011139249A3 (en) Pharmaceutical composition comprising cefdinir
MX338629B (es) Composiciones farmaceuticas de ibuprofeno y un antagonista del receptor de h2.
MX353991B (es) Agonista del receptor de 5-ht4 como agente procinetico.
MX2010011193A (es) Composicion farmaceutica liquida para el tratamiento y prevencion del dolor.
EP2172218A4 (en) METHOD FOR SCREENING A PATIENT WHICH SHOULD ADMINISTER A PHARMACEUTICAL AGENT COMPRISING ANTICANCER ANTIBODY AS AN ACTIVE INGREDIENT

Legal Events

Date Code Title Description
FG Grant or registration